AI English summary of an SEC filing — figures as filed
Boston Scientific BSXThe company said the Board of Directors, on February 18, 2026, increased the Board from 10 to 12 members and appointed Catherine R. Smith and Christophe P. Weber as directors, each to serve until the next annual meeting of stockholders.
Key points
AI summaryThe company said the Board of Directors, on February 18, 2026, increased the Board from 10 to 12 members and appointed Catherine R. Smith and Christophe P. Weber as directors, each to serve until the next annual meeting of stockholders.
The company said it assigned Smith to the Audit Committee and the Nominating and Governance Committee, and Weber to the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee, effective February 23, 2026.
The company said each new director will receive prorated standard non-employee director compensation, including a cash retainer of about $24,663 and equity awards valued at about $42,420. It also said the Board on February 18, 2026 raised the existing $1.0 billion common stock repurchase authorization by $4.0 billion to a total of $5.0 billion, all of which remains available.
The company said in its press release that Smith is chief financial officer of Starbucks and Weber is president and chief executive officer of Takeda Pharmaceutical. The appointments followed the previously announced retirements of John Sununu and Yoshiaki Fujimori, who will serve until the 2026 annual meeting of stockholders.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Board Expands to 2 Members and Appoints New Directors
The company said the Board of Directors, on February 18, 2026, increased the Board from 10 to 12 members and appointed Catherine R. Smith and Christophe P. Weber as directors, each to serve until the next annual meeting of stockholders.
Source · Based on the filing body and exhibits
New Directors Assigned to Board Committees
The company said it assigned Smith to the Audit Committee and the Nominating and Governance Committee, and Weber to the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee, effective February 23, 2026.
Source · Based on the filing body and exhibits
New Director Compensation and Increase in Share Repurchase Authorization
The company said each new director will receive prorated standard non-employee director compensation, including a cash retainer of about $24,663 and equity awards valued at about $42,420. It also said the Board on February 18, 2026 raised the existing $1.0 billion common stock repurchase authorization by $4.0 billion to a total of $5.0 billion, all of which remains available.
Source · Based on the filing body and exhibits
New Directors' Backgrounds and Timing of Existing Directors' Retirements
The company said in its press release that Smith is chief financial officer of Starbucks and Weber is president and chief executive officer of Takeda Pharmaceutical. The appointments followed the previously announced retirements of John Sununu and Yoshiaki Fujimori, who will serve until the 2026 annual meeting of stockholders.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…